Co-Founder, Chief Executive Officer of ARMADYNE Corp. James Ryan is the father of a seriously ill child. For nearly 20 years, James Ryan has been deeply involved in pioneering research and development of cutting edge clinical translation of various types of regenerative medicine platforms after an experimental clinical translation of stem cell therapy helped save his infant sons life in 1998. In 1999, he established the first pluripotent stem cell company in Japan Jimmy’s Investment Group Corporation to develop a cure for his son, Jimmy. He began developing, investing, and accelerating disruptive regenerative medicine technology in 2000 when he established business/research relationship with RGI (Reproductive Genetics Institute). in 2004 he established "Asclepius Therapeutics", a Joint venture with Dr. Yury Verlinsky and Reproductive Genetics Institute, he served as its Chief Executive Officer, Co-founding the World's First Patient-specific Pluripotent Stem Cell Company, utilizing -somatic Cell Reprogramming STEMBRID Technology. Co-founded several other regenerative companies, and recently served as Chief Executive Officer of Omgeneum Inc. He is the current CEO of Armadyne Corp. and has deep knowledge of regenerative medicine and almost two decades of research and development of cutting edge technology.